Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP)

被引：0
|
作者：
Hassel, J. [1 ,2 ]
Forschner, A. [3 ]
Bluhm, L. [4 ]
Heinzerling, L. [5 ]
Zimmer, L. [6 ]
Utikal, J. [7 ,8 ]
Kaehler, K. [9 ]
Schlaak, M. [10 ]
Loquai, C. [11 ]
Gutzmer, R. [12 ]
Kieker, F. [13 ]
Berking, C. [14 ]
Bender, A. [15 ]
Schneider, L. [16 ]
Enk, A. [1 ,2 ]
Garbe, C. [3 ]
Weichenthal, M. [9 ]
Schadendorf, D. [6 ]
Hauschild, A. [9 ]
Mohr, P. [4 ]
机构：
[1] Univ Klinikum Heidelberg, Hautklin, Heidelberg, Germany
[2] Univ Klinikum Heidelberg, NCT, Heidelberg, Germany
[3] Univ Klinikum Tubingen, Hautklin, Tubingen, Germany
[4] Elbe Klinikum Buxtehude, Hautklin, Buxtehude, Germany
[5] Univ Klinikum Erlangen, Hautklin, Erlangen, Germany
[6] Univ Klinikum Essen, Hautklin, Essen, Germany
[7] DKFZ, Heidelberg, Germany
[8] Univ Klinikum Mannheim, Klin Kooperat Einheit Dermatoonkol, Heidelberg, Germany
[9] Univ Klinikum Kiel, Hautklin, Kiel, Germany
[10] Univ Klinikum Koln, Hautklin, Cologne, Germany
[11] Univ Klinikum Mainz, Hautklin, Mainz, Germany
[12] Univ Klinikum Hannover, Hautklin, Hannover, Germany
[13] Charite Univ Klinikum, Hautklin, Berlin, Germany
[14] Univ Munchen LMU, Hautklin, Munich, Germany
[15] Univ Klinikum Marburg, Hautklin, Marburg, Germany
[16] Univ Klinikum Ulm, Hautklin, Ulm, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2016年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV19
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [21] PEMBROLIZUMAB FOR METASTATIC MELANOMA - ONE YEAR RESULTS OF NAMED PATIENT ACCESS PROGRAM
    Atkinson, Victoria G.
    Andelkovic, Vladimir
    Gunawan, Benjamin
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 117 - 117
  • [22] The impact of brain involvement in metastatic melanoma patients treated with pembrolizumab
    Weichenthal, Michael
    Emilie, Scherrer
    Chandwani, Sheenu
    Mohr, Peter
    Leiter, Ulrike
    Ugurel, Selma
    Kaehler, Katharina C.
    Gutzmer, Ralf
    Pfoehler, Claudia
    Hassel, Jessica
    Terheyden, Patrick
    Schell, Beatrice
    Utikal, Jochen
    Kreuter, Alexander
    Haferkamp, Sebastian
    Sindrilaru, Anca
    Hassel, Jessica
    Nashan, Dorothee
    Kaune, Kjell M.
    Berking, Carola
    Debus, Dirk
    Ulrich, Jens
    Dabrowski, Evelyn
    Eigentler, Thomas
    Herbst, Rudolf
    Welzel, Julia
    Loquai, Carmen
    Meier, Friedegund
    Schadendorf, Dirk
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (SUPPL 1)
  • [23] IPILIMUMAB (IPI) EXPANDED ACCESS PROGRAM (EAP) FOR PATIENTS (PTS) WITH STAGE III/IV MELANOMA: SAFETY DATA BY SUBGROUPS
    Lawrence, D.
    McDermott, D. F.
    Hamid, O.
    Weber, J. S.
    Wolchok, J. D.
    Richards, J.
    Amin, A.
    Bennett, K.
    Balogh, A.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 368 - 368
  • [24] Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)
    Lin, M. M.
    Pan, X.
    Hou, P.
    Allen, S.
    Baumann, P.
    Hochmair, M. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 42 - 42
  • [25] Avelumab treatment of Australian patients with metastatic Merkel cell carcinoma (mMCC): Experience from an expanded access program (EAP)
    van Hagen, Tom
    Sandhu, Shahneen
    Kasturi, Vijay
    Steer, Christopher
    Khoo, Chloe
    Nordman, Ina
    Hennessy, Meliessa
    Hildemann, Steven
    Reed, Josh
    Hariharan, Subramanian
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 173 - 174
  • [26] Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)
    Bracarda, S.
    Galli, L.
    Maruzzo, M.
    Lo Re, G.
    Buti, S.
    Favaretto, A.
    Costanzo, F. D.
    Sacco, C.
    Merlano, M.
    Mucciarini, C.
    Zafarana, E.
    Romito, S.
    Maestri, A.
    Giorgio, C. Giannitto
    Ionta, M. T.
    Turci, D.
    De Giorgi, U.
    Procopio, G.
    Cortesi, E.
    Porta, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Global Expanded Access Program (EAP) to pemigatinib for patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements
    Lindley, Anouk
    Prager, Gerald
    Bitzer, Michael
    Burn, Timothy C.
    Lihou, Christine F.
    Richards, Elisabeth Croft
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 82 - 82
  • [28] SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher D.
    Gonzalez, Rene
    Daniels, Gregory A.
    Thompson, John A.
    Kudchadkar, Ragini R.
    Sharfman, William H.
    Atkins, Michael B.
    Pavlick, Anna C.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Weber, Jeffrey S.
    Nair, Suresh
    Cowey, Lance
    Lipson, Evan J.
    Lee, Sue
    Avila, Alexandre
    Hodi, Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 119 - 119
  • [29] Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher
    Gonzalez, Rene
    Daniels, Gregory A.
    Thompson, John A.
    Kudchadkar, Ragini Reiney
    Sharfman, William Howard
    Atkins, Michael B.
    Pavlick, Anna C.
    Infante, Jeffrey R.
    Kim, Kevin
    Weber, Jeffrey S.
    Patel, Sapna Pradyuman
    Nair, Suresh
    Cowey, C. Lance
    Lipson, Evan J.
    Lee, Sue
    Avila, Alexandre
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM).
    Bloss, J
    Wozniak, A
    Janne, P
    Belani, C
    Keohan, M
    Ross, H
    Polikoff, J
    Mintzer, D
    Bloss, L
    Obasaju, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 665S - 665S
12345